Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > UK consensus group calls for biomarker testing at point of diagnosis
  • News

UK consensus group calls for biomarker testing at point of diagnosis

  • 8 September 2022
  • Janet Fricker
UK consensus group calls for biomarker testing at point of diagnosis
Total
0
Shares
0
0
0
0
0

All cancer patients should be offered genomic profiling of their tumours at the point of diagnosis and during treatment to shape care and track how their disease evolves and responds to treatment. These were the conclusions of a UK consensus group, convened by the Institute of Cancer Research, London, published in July 2022, which said it was critical for the National Health Service (NHS) to ensure patients can access more personalised and effective treatments as part of standard of care.

“It’s essential that the regulations that govern clinical trials and the approval of new tests and treatments keep pace with the rapidly moving science,” says Kristian Helin, Chief Executive of the Institute of Cancer Research, London. “At the moment, it can be hard to get new biomarker tests developed, approved and made available for patients. That can in turn act as a disincentive for companies and academics to develop new biomarkers to guide treatment in the future.”

Biomarker tests look for genetic, protein or imaging ‘markers’ to identify which patients are most likely to respond to treatment. “Biomarker tests can direct treatment precisely to the patients who will most benefit, which can both improve the lives of patients and increase the cost-effectiveness of treatment for the NHS,” explains Helin.
The consensus group, convened by the Institute of Cancer Research, included nine leading institutions, charities, stakeholder groups and life-science companies: Cancer Research UK, the Association of the British Pharmaceutical Industry, Association of British HealthTech Industries (ABHI) and Leukaemia UK, along with the drug companies AbbVie, AstraZeneca, Bioclavis, Bristol Myers Squibb, and Precision Life.

The consensus group issued a series of 13 statements calling for a series of changes in the way biomarker tests are developed, made available and routinely used in the UK. Changes identified include:

  • Increasing the number of precision medicines developed with a companion biomarker test to direct treatment precisely at those patients who benefit most. To achieve this, barriers to pharmaceutical and diagnostic companies developing biomarkers alongside drugs need to be removed, with the provision of new incentives.
  • Making regulation of biomarker tests used in clinical trials fit for purpose by taking into consideration the ways biomarker tests are used in research and treatment when reviewing clinical trial proposals.
  • Governments encouraging collaborations between public institutions and companies on biomarker research and sharing risk between public and private sectors.
  • Health technology assessment bodies, such as The National Institute for Health and Care Exellence (NICE), taking a more positive view of use of companion biomarker tests alongside new drugs. The NHS should explore the possibility of offering subsidies for companies bringing forward biomarker tests alongside new treatments.
  • Retaining flexibility by ensuring cancer treatments are not tied to one specific named biomarker test.
  • Exploring development of biomarkers tests as early as possible in the discovery of a drug so they can be refined, and robust evidence generated on use ahead of evaluation.
  • Retrospectively developing biomarkers and companion biomarker tests for drugs that already exist to improve and guide use of existing cancer treatments.
  • Making molecular profiling of all people with cancer standard-of-care to identify mutations and guide treatment.
  • Using broad genomic panels to test for many different cancer mutations at the same time. Including large numbers of genes increases the chance of detecting important cancer mutations and furthermore identifies future biomarkers that can be used to predict treatment response and other aspects of prognosis.
  • Establishing a broader and more transparent directory of biomarker tests including non-genomic tests, e.g. immunohistochemistry testing.
  • Encouraging clinicians to talk to patients about biomarker testing at the point of diagnosis to promote shared decision making.
  • Undertaking an analysis of workforce challenges around biomarker use (e.g. bottlenecks impeding implementation and training requirements) so that these can be addressed.
  • Conducting regular benchmarking of how the UK compares on implementing biomarkers against international comparators.

Commenting on the consensus statement, Mark Lawler, a member of the Board of the Cancer Drug Development Forum (CDDF), says, “I welcome the conclusions of this consensus group, which offers a pragmatic approach by focusing on what can practically be achieved in real-world settings, as opposed to aspirational targets only achievable in clinical trials and research studies.”

Lawler, expressed disappointment, however, at not seeing greater patient involvement. “The word ‘patient’ is used once in the 13 recommendations. Cancer patients must be placed firmly at the centre of a cancer-biomarker-informed precision oncology care agenda, as stated in Europe’s Beating Cancer Plan and the European Code of Cancer Practice. Having the patient voice articulated more would allow you to better understand the barriers faced in accessing biomarkers and treatment,” says Lawler, who is chair in Translational Cancer Genomics at Queen’s University Belfast.

While the consensus was written from the UK perspective, Lawler believes there are many universal aspects that equally apply across Europe, including enhancing precision oncology, ensuring multigene testing, supporting shared decision-making, and creating public‒private partnerships.

But with the new European In Vitro Diagnostics Regulation (IVDR), which came into force in May 2022, Europe faces its own challenges.  “The new legislation makes it more difficult for laboratory developed biomarker tests to be used as opposed to commercial tests. We’re concerned that going forward this could act as a deterrent to innovation, and ultimately prevent the development of improved, quicker and cheaper tests,” he says.

Other concerns in Europe include unequal access to biomarker tests. “There’s a postcode lottery in Europe at the moment. Where patients live determines whether they can get access to a biomarker assessment. The reality is that biomarker tests offer the gateway to accessing many new cancer medicines, and if patients can’t access the tests, they won’t be able to access the medicines,” says Lawler.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • personalised medicine
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

Frequent aspirin use associated with ovarian cancer risk-reduction

  • 7 September 2022
  • Janet Fricker
View Post
Next Article
  • Articles
  • Policy

Delivering cervical cancer screening across India: the plan… and the practice

  • 9 September 2022
  • Swagata Yadavar
View Post
You May Also Like
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • News

Call-to-arms for Europe to provide essential paediatric anti-cancer medicines

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Exercise-stimulated myokine production can extend survival in advanced prostate cancer

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Five San Antonio take-aways to improve care of breast cancer patients

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Repurposed drug combination reduces risk of recurrence following surgery for colorectal cancer

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Aerobic activity to outcompete metastasis 

  • Janet Fricker
  • 2 December 2022
View Post
  • News

Ending cancer inequalities: European summit showcases new tools to inform policy

  • Anna Wagstaff
  • 30 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • Hansjörg Senn of St Gallen: A practice-changing career
    • 3 February 2023
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.